Loading
A phase 1/2 trial of Raludotatug deruxtecan, Carboplatin, Paclitaxel / nab-paclitaxel in ovarian cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) is a phase 1/2 interventional study registered as NCT06843447 by Merck Sharp & Dohme LLC, with 605 participants planned, started 2025-04-15 and due to reach its primary completion in 2029-03-27. Interventions recorded: Raludotatug Deruxtecan, Carboplatin, Paclitaxel, Bevacizumab, Rescue Medication. Conditions listed: Ovarian Cancer Recurrent. No results are recorded here; the registry entry is the source.
Shares High-grade serous ovarian cancer, Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
Shares Raludotatug deruxtecan, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Raludotatug deruxtecan, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Raludotatug deruxtecan, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Raludotatug deruxtecan, Merck & Co. (MSD).
Shares High-grade serous ovarian cancer, Antibody-drug conjugate (ADC), Ovarian cancer.